-
Study aim
-
This study aims to formulate a topical diclofenac potassium gel and evaluate its effectiveness in managing primary dysmenorrhea. It also seeks to compare the pain-relieving effects of the gel alone versus in combination with Transcutaneous Electrical Nerve Stimulation (TENS) to determine the potential benefit of combined therapy.
-
Design
-
Pragmatic, community based, parallel group, double blinded, randomized controlled trial. Total 376 patients will be enrolled. Patients who met our inclusion criteria will be randomized into two groups.
-
Settings and conduct
-
The trial will be held at Muhammad Physical Therapy & Rehabilitation Center, Multan. It is single-blinded, with participants unaware of their group. Treatments will be in identical boxes, and codes kept by the principal investigator.
-
Participants/Inclusion and exclusion criteria
-
Inclusion Criteria Woman (18-45 years), Female diagnosed with primary or secondary dysmenorrhea, Regular menstrual cycles (21-35days), Females, Moderate to severe menstrual pain, Intervention was physiotherapy techniques (electro-physical agents, massage, exercise). Exclusion Criteria Pregnancy Females with bleeding disorders, Breast feeding, Uterine fibroids, Adenomyosis , Endometriosis, Pelvic inflammatory disease, Menstrual disorder
-
Intervention groups
-
Group A will receive 6% diclofenac potassium gel plus TENS, while Group B will use the gel alone. Both groups will apply 2–4 grams of gel 2–4 times daily for up to three days. Group A will also get Transcutaneous Electrical Nerve Stimulation (80–100 Hz, 20–30 minutes, 2–3 times daily) to enhance pain relief.
-
Main outcome variables
-
range of motion, joint stiffness, independency and quality of life